A carregar...
Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson’s disease: an open-label study
BACKGROUND: Achieving optimal symptom control with minimal side effects is a major goal in clinical practice. Dual-agent dopamine receptor agonist (DA) therapy in Parkinson’s disease (PD) may represent a promising approach to treatment, as the combination of different pharmacokinetic/pharmacological...
Na minha lista:
| Publicado no: | BMC Neurol |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4364324/ https://ncbi.nlm.nih.gov/pubmed/25879416 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12883-015-0267-7 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|